Search research articles
Contact Us
Filters
Showing results (161-170 of 284) with videos related to
Page
of 29
Sort By:
Radiation Oncology (London, England)
|
January 16, 2020
The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer
Sophia C Kamran, Thibaud Coroller, Nastaran Milani, et al.
Journal of Cellular and Molecular Medicine
|
December 2, 2008
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
Justine A Barletta, Sven Perner, A John Iafrate, et al.
Journal of the National Cancer Institute
|
August 18, 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
Toru Mukohara, Jeffrey A Engelman, Nasser H Hanna, et al.
JTO Clinical and Research Reports
|
May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLC
Bruce E Johnson, Christina S Baik, Julien Mazieres, et al.
Cancer
|
September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer
Sinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Bruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2006
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Pasi A Jänne, Ana M Borras, Yanan Kuang, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Masahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2009
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
Emer O Hanrahan, Heather Y Lin, Edward S Kim, et al.
Page
of 29
Search research articles
Search
Showing results (161-170 of 284) with videos related to
Sort By:
Page
of 29
Radiation Oncology (London, England)
|
January 16, 2020
The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer
Sophia C Kamran, Thibaud Coroller, Nastaran Milani, et al.
Journal of Cellular and Molecular Medicine
|
December 2, 2008
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma
Justine A Barletta, Sven Perner, A John Iafrate, et al.
Journal of the National Cancer Institute
|
August 18, 2005
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
Toru Mukohara, Jeffrey A Engelman, Nasser H Hanna, et al.
JTO Clinical and Research Reports
|
May 20, 2022
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLC
Bruce E Johnson, Christina S Baik, Julien Mazieres, et al.
Cancer
|
September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer
Sinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Bruce E Johnson, Fairooz Kabbinavar, Louis Fehrenbacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2006
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Pasi A Jänne, Ana M Borras, Yanan Kuang, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Masahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2009
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer
Emer O Hanrahan, Heather Y Lin, Edward S Kim, et al.
Page
of 29